Author

Sujani Nannapaneni

Institution: AbbVie (United States)

Observed institution: AbbVie (United States)

OpenAlex ID: A5004100768

Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn’s Disease

2023 · Edward V. Loftus, Jenny Griffith, et al. · Advances in Therapy · 16

Clinical Bridging From Prefilled Syringe to On-body Injector for Risankizumab in Crohn's Disease

2023 · Yinuo Pang, Ronilda D'Cunha, et al. · Clinical Therapeutics · 14

S38 On-Body Injector Administration of Risankizumab for Treatment of Moderate-to-Severe Crohn’s Disease: Data From the Fortify Open-Label Longitudinal Real-Life Handling Substudy

2022 · Edward Loftus, Jenny Griffith, et al. · The American Journal of Gastroenterology · 2

Works count: 3

Citation count: 32

H-index: 2

I10-index: 2